DR² ThinkTech
Questions about AI in healthcare, medical automation, clinical AI validation, FHIR, HL7, clinical RAG, medical regulation, and governance.
The initial assessment maps care delivery, documents, data used, decision points, and risks before recommending any automation. The first gain usually shows up where there is repetition: pre-visit intake, information organization, reports, checklists, and indicators.
Yes, when the use stays within administrative routines or materials with no sensitive data. Scheduling, standardized instructions, operational triage, and document organization come before the medical record. Once clinical information appears, LGPD, human review, and an audit trail come into play.
The clinic needs to know its documents, systems, spreadsheets, visit types, bottlenecks, and sensitive data. If the workflow is confusing, the AI inherits the confusion. The first step is turning an invisible routine into a documented process.
If the problem is records, scheduling, billing, or inventory, a regular system solves most of it. If the problem involves text, decisions, prioritization, protocols, document analysis, or pattern reading, AI comes in as an added layer. The right question is: which task today depends on repeated human interpretation?
Not always. In smaller projects, DR² handles the technical side with the existing team. For integration with a medical record system, API, FHIR, or database, the vendor's or institution's IT team joins the project.
It does, when the summary stays tied to authorized documents, with source identification and human review. The risk starts when the system mixes passages, infers what was not written, or turns missing information into a finding. A clinical summary needs to carry uncertainty along with the data.
It helps when it organizes pending items, risks, pending tests, ongoing courses of action, devices, and warning signs. A safe shift handoff is not nice-sounding text; it is a risk transfer without losing context.
The AI compares documents, dates, prescriptions, progress notes, and pending items against defined criteria. It flags inconsistencies and missing records; the audit team decides relevance. The gain is tracking signals that manual review misses.
Purpose, approved tools, prohibited data, owners, human review, logs, training, exceptions, incidents, and how to suspend use. The policy needs to fit into the flow from front desk to physician.
The risk is putting sensitive data outside an approved environment, without a contract, access control, or a record. The institution loses track of where the data was used. Invisible use tends to look like a shortcut until it turns into an incident.
Remove direct identifiers, reduce re-identifiable details, and assess dates, locations, rare combinations, and free text. In health care, weak anonymization doesn't protect anyone. A rare case with only a few data points can still identify someone.
Check for missing fields, duplicates, wrong dates, inconsistent codes, unstandardized free text, and routine changes over time. AI does not fix bad data by miracle. It amplifies either the organization or the disorder already there.
The architecture needs to limit the content sent, log calls, control keys, vet vendors, and block sensitive data without authorization. An API is not a neutral channel. Everything that leaves the system needs a purpose and an audit trail.
It helps because the medical record stores data, but does not turn that data into a useful workflow. Many medical records hold information; few organize decisions, alerts, indicators, and audits. DR² works at that layer of use.
When data is scattered, interoperability comes first. When the problem is documental and narrow, AI can start with a smaller base. The order comes from one question: does the solution need to read live data from multiple systems, or a closed document?
Not always. Many solutions use off-the-shelf models with controlled context, rules, RAG, and validation. Training a model on proprietary data only makes sense when there is volume, quality, and a technical justification.
The design should limit the source, log the context, require answers with references, and build in review points. In a clinical setting, a fluent answer is not enough. The system needs to show where the information came from and when it lacks sufficient basis.
Use a restricted source, required fields, logs, human review, and blocks for missing information. The system should flag it when data is missing for technical closure. Documentation errors usually start with an empty field treated as a certainty.
Validate context, data source, population, expected error, limits, review workflow, and monitoring. A metric on its own is not enough. The central question is whether the error becomes visible before it reaches the patient.
Look for outputs with no source, low human pushback, missing logs, performance drops within a subgroup, and protocol changes without new testing. A silent error keeps looking normal. In health care, that is a sign of risk.
The answer depends on the contract, the use, human review, the type of system, and the harm involved. That is why governance must log version, input data, output, review, and final decision. Responsibility without an audit trail turns into a blind dispute.
Measure error by case type, subgroup, scenario, data source, and time. Include hallucination rate, human disagreement, false alarms, missed alerts, and drift. Clinical safety comes from visible error, not a flattering average.
Useful AI delivers something practical. Trustworthy AI delivers that value with limits, traceability, testing, and review. In health care, usefulness without governance creates risk that looks presentable.
Testing combines synthetic cases, authorized historical data, specialist review, error scenarios, and workflow analysis. The solution has to answer simple questions: where did the answer come from, when does it fail, who reviews it, and how do you suspend it?
The interface should invite review, show uncertainty, expose the source, and create a stopping point. If the screen feels like it gives a final answer, the team tends to accept it. Screen design is also a risk control.
Define operational contraindications: incomplete data, a patient outside the profile, a poor-quality document, an expired protocol, low confidence, no review, or a relevant change in the workflow. A safe system knows how to say no.
Ask for the purpose, technical basis, data used, limits, logs, validation, security, contract, liability, support, and an offboarding plan. A vendor who cannot explain a failure should not be part of a sensitive clinical process.
It doesn't eliminate it. It reduces the risk when the answer stays anchored to a source, context, and citation rule. You still need to test cases, review answers, and define when the system should say it found no basis.
It works as a document review layer: it checks fields, attachments, deadlines, codes, justifications, and discrepancies. It doesn't eliminate claim denials on its own. It reduces surprises when the audit rule is built into the workflow.
You can estimate operational risk using history, arrivals, length of stay, beds, tests, and peak hours. Forecasting does not fix a bed shortage; it gets ahead of the decision. The value shows up when the alert arrives before the flow collapses.
It helps as support, as long as it respects protocol, warning signs, and human review. Risk classification is not an ordinary form. A single error changes care priority.
The mistake is judging the tool by the model's name instead of its clinical function. An administrative AI, a SaMD, an ambient scribe, and a decision support tool each carry different risks. The correct analysis starts with purpose, consequence, data used, review, and applicable regulation.
DR² helps healthcare institutions assess, validate, and deploy clinical AI with care safety, traceability, governance, and evidence of value. Deployment starts from the real workflow, available data, clinical risk, LGPD (Brazilian data protection law), human review, and the indicators that demonstrate usefulness before scaling.
Before automating, we map the workflow. Before scaling, we validate the risk. Before promising results, we measure data, process, human review, and impact. This order reduces poorly targeted automation and creates an auditable trail for the institutional decision.
The track organizes Clinical AI Diagnosis, covering workflow, data, risk, LGPD (Brazilian data protection law), operational readiness, and a decision plan; Healthcare AI Validation, covering local testing, safety criteria, human review, logs, metrics, fallback, and usage limits; Assisted Deployment, covering integration into clinical routine, training, indicators, and governance; Institutional Training, for physicians, managers, IT, quality, compliance, legal, and care teams; and the DR² Lab, covering agents, prototypes, clinical RAG, automations, dashboards, tools, and applied research.
You do not need to know how to code to start using AI in your medical routine. Initial learning involves choosing a task, recognizing the tool's errors, and checking the result. Programming becomes important when the goal is to develop a solution or integrate systems.
Evaluate the tool against the problem it is meant to solve. Ask for evidence from the intended use setting, results by patient profile, and information about failures. The contract needs to define how outputs will be reviewed, how results will be monitored, and the criteria for suspending use. In patient care, clinical decisions remain with the physician.
